Remove 2007 Remove FDA Approval Remove Treatment
article thumbnail

Automated red blood cell exchange: bridging treatment gaps in sickle cell disease care

Drug Target Review

Dr Aaron Haubner, Senior Manager of North America Medical Affairs and Market Access at Terumo Blood and Cell Technologies , reveals that while promising new treatments emerge, urgent partnerships are needed to ensure this essential blood therapy reaches the patients who need it most.

Disease 52
article thumbnail

Gepirone

New Drug Approvals

4] It was approved for the treatment of major depressive disorder in the United States in September 2023. [4] 4] This came after the drug had been rejected by the Food and Drug Administration (FDA) three times over two decades due to insufficient evidence of effectiveness. [5] 1] It is taken orally. [1] 1] It is taken orally. [1]

FDA 62
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Inavolisib

New Drug Approvals

3] Inavolisib was approved for medical use in the United States in October 2024. [3] 3] Inavolisib was approved for medical use in the United States in October 2024. [3] 1, 2007, 41-44) (2.30 8] Therefore, it may serve as a new addition to combination therapy with conventional cancer treatment, such as chemotherapy.

FDA 57
article thumbnail

2025 Merkin Prize in Biomedical Technology awarded to pioneers of CAR T-cell therapy

Broad Institute

The work of June, Levine, Rivire, and Sadelain laid the foundation for a whole new class of treatments. In 2007, Sadelain and Rivire treated their first patient with leukemia, and in 2009, published details on how they manufactured personalized CAR T cells to treat patients with aggressive leukemia.

Therapies 119
article thumbnail

PRITELIVIR MESYLATE

New Drug Approvals

It is being investigated as a potential treatment for various herpes infections, including those resistant to traditional antivirals like acyclovir. Pritelivir (development codes AIC316 or BAY 57-1293 ) is a direct-acting antiviral drug in development for the treatment of herpes simplex virus infections (HSV).

Virus 62
article thumbnail

Landiolol

New Drug Approvals

Landiolol 133242-30-5 ONO-1101 Ono 1101 WHO 7516 FDA APPROVED 11/22/2024, Rapiblyk , To treat supraventricular tachycardia C25H39N3O8 509.6 Landiolol 133242-30-5 ONO-1101 Ono 1101 WHO 7516 FDA APPROVED 11/22/2024, Rapiblyk , To treat supraventricular tachycardia C25H39N3O8 509.6 9] It is used as landiolol hydrochloride.

FDA 62
article thumbnail

Seladelpar

New Drug Approvals

4] Seladelpar was approved for medical use in the United States in August 2024. [1] 4] Seladelpar was approved for medical use in the United States in August 2024. [1] 2007 Jul 15;17(14):3855-9. 2007 Jul 15;17(14):3855-9. Epub 2007 May 10. Seladelpar cas 851528-79-5 C 21 H 23 F 3 O 5 S, 444.47 doi: 10.1016/j.bmcl.2007.05.007.

FDA 62